The estimated Net Worth of Helen Susan Kim is at least $20.8 million dollars as of 26 August 2021. Ms. Kim owns over 15,014 units of Assembly Biosciences Inc stock worth over $9,993,500 and over the last 15 years she sold ASMB stock worth over $10,604,961. In addition, she makes $159,707 as Independent Director at Assembly Biosciences Inc.
Sign up
Ms. Kim ASMB stock SEC Form 4 insiders trading
Helen has made over 20 trades of the Assembly Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she sold 15,014 units of ASMB stock worth $453,573 on 26 August 2021.
The largest trade she's ever made was exercising 800,000 units of Assembly Biosciences Inc stock on 2 July 2020 worth over $16,000. On average, Helen trades about 33,077 units every 56 days since 2009. As of 26 August 2021 she still owns at least 575,000 units of Assembly Biosciences Inc stock.
You can see the complete history of Ms. Kim stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Helen Kim biography
Helen S. Kim serves as Independent Director of the Company. Ms. Kim joined our Board in March 2018. Since April 2019, Ms. Kim has been a managing director at Vida Ventures. Prior to that, from March 2018 until April 2019, Ms. Kim was a partner at The Column Group, a science-driven venture capital firm that invests in private companies. From November 2014 until January 2018, Ms. Kim served as executive vice president of business development at Kite Pharma, Inc. where she led all business and corporate development initiatives including its sale to Gilead Sciences, Inc. (Gilead) in September 2017. From January 2012 to January 2014, Ms. Kim served as strategic advisor to NGM Biopharmaceuticals, Inc. and from August 2009 to January 2012, Ms. Kim served as chief business officer of NGM Biopharmaceuticals, Inc. Ms. Kim’s additional industry experience includes executive positions at Kosan Biosciences, Affymax, Inc., Onyx Pharmaceuticals, Inc., Protein Design Labs, Inc. and Chiron Corporation. In addition to her industry experience, from August 2003 to November 2007, Ms. Kim served as chief program officer for the Gordon and Betty Moore Foundation. Currently, she serves as a director on the board of Exicure, Inc., a public company, and Applied Molecular Transport Inc., A2 Biotherapeutics, Inc., PACT Pharma, Inc. and ReCode Therapeutics, Inc., each of which is a private company. Ms. Kim formerly served as a director and member of the audit committee of Sunesis Pharmaceuticals, Inc. and WCCT Global, Inc. and a director of Forsight Labs, Vision 4. Ms. Kim received a B.S. in Chemical and Biomedical Engineering from Northwestern University and an M.B.A. from the University of Chicago.
What is the salary of Helen Kim?
As the Independent Director of Assembly Biosciences Inc, the total compensation of Helen Kim at Assembly Biosciences Inc is $159,707. There are 13 executives at Assembly Biosciences Inc getting paid more, with John McHutchison having the highest compensation of $7,007,210.
How old is Helen Kim?
Helen Kim is 57, she's been the Independent Director of Assembly Biosciences Inc since 2018. There are 10 older and 9 younger executives at Assembly Biosciences Inc. The oldest executive at Assembly Biosciences Inc is Alan Lewis, 74, who is the Independent Director.
What's Helen Kim's mailing address?
Helen's mailing address filed with the SEC is C/O PROTHENA BIOSCIENCES INC, 1800 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at Assembly Biosciences Inc
Over the last 10 years, insiders at Assembly Biosciences Inc have traded over $1,523,622 worth of Assembly Biosciences Inc stock and bought 1,245,980 units worth $1,060,065 . The most active insiders traders include Sciences, Inc. Gilead, Myron Z Holubiak et Helen Susan Kim. On average, Assembly Biosciences Inc executives and independent directors trade stock every 46 days with the average trade being worth of $389,399. The most recent stock trade was executed by Nicole S White on 2 August 2024, trading 785 units of ASMB stock currently worth $11,171.
What does Assembly Biosciences Inc do?
assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora
What does Assembly Biosciences Inc's logo look like?
Complete history of Ms. Kim stock trades at Assembly Biosciences Inc, Prothena plc, Sunesis Pharmaceuticals Inc, Exicure Inc et Applied Molecular Transport
Assembly Biosciences Inc executives and stock owners
Assembly Biosciences Inc executives and other stock owners filed with the SEC include:
-
John McHutchison,
President, Chief Executive Officer, Director -
Jacqueline Papkoff,
Senior Vice President, Chief Scientific Officer Microbiome -
Thomas Joseph Russo,
Chief Financial Officer -
Luisa Stamm,
Chief Medical Officer -
Dr. John G. McHutchison A.O., FRACP, M.D.,
CEO, Pres & Director -
Jason A. Okazaki,
Chief Operating Officer -
Dr. William E. Delaney IV, Ph.D.,
Chief Scientific Officer -
William Ringo,
Non-Executive Independent Chairman of the Board -
Myron Holubiak,
Independent Director -
Alan Lewis,
Independent Director -
Anthony Altig,
Independent Director -
Susan Mahony,
Independent Director -
Richard DiMarchi,
Independent Director -
Helen Kim,
Independent Director -
Nicole White,
Senior Vice President - Pharmaceutical Development and Manufacturing -
Gina Consylman,
Independent Director -
Jason Okazaki,
Chief Legal and Business Officer -
William Delaney,
Chief Scientific Officer - Virology -
Steven Knox,
Senior Vice President - Clinical Development -
David Houck,
Senior Vice President - Product Development and Portfolio Management -
Michele Anderson,
Chief Devel. Officer -
Dr. Tharaknath Rao,
Head of Microbiome Clinical Devel. & Sr. VP -
Dr. Richard J. Colonno,
Sr. Advisor -
Jennifer A. Troia MHROD, SHRM-SCP, SPHR,
Chief HR Officer -
Lauren Glaser,
Sr. VP of Investor Relations & Corp. Affairs -
Michael P. Samar,
CFO & Principal Accounting Officer -
Dr. Adam Zlotnick,
Co-Founder, Chief Scientific Advisor and Chair of Hbv & Virology Science Advisory Board -
Dr. Uri A. Lopatin M.D.,
Co-Founder and Clinical & Scientific Advisor -
Graham K Cooper,
See Remarks -
Mark Auerbach,
Director -
David Jonathan Barrett,
See Remarks -
Thomas E Rollins,
Chief Development Officer -
Uri A Lopatin,
Chief Medical Officer -
Michael Houghton,
-
Derek A Small,
Director -
Richard James Colonno,
EVP & CSO, Virology Ops -
Capital Fund Qualified, L.P...,
10% owner -
Lisa Johnson Pratt,
-
Anuj Gaggar,
Chief Medical Officer -
Adam Zlotnick,
10% owner -
Sciences, Inc. Gilead,
10% owner -
Michael P. Samar,
Chief Financial Officer -
Jeanette M Bjorkquist,
Principal Accounting Officer -
Alexander Schornstein,
10% owner